Fluorine-18 radiolabeled heterocycles as PET tracers for imaging β-amyloid plaques in Alzheimer's disease

Current Topics in Medicinal Chemistry

Volumn 13, Issue 8, 2013, Pages 909-919

  Zeng, Fanxing ^a   Goodman, Mark M ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

amyloid plaques; Alzheimer's disease; Fluorine 18; Heterocycles; PET imaging; Radioligands

Indexed keywords

AMINO NAPHTYL DERIVATIVE; AMYLOID BETA PROTEIN; BENZOFURAN DERIVATIVE; BENZOTHIAZOLE; BENZOXAZOLE DERIVATIVE; FLORBETABEN; FLORBETAPIR F 18; FLUORINE 18; FLUTEMETAMOL F 18; IMIDAZO [4, 5 C] PYRIDINE DERIVATIVE; MACROGOL; MALONONITRILE; NAPHTHOL DERIVATIVE; PYRIDAZINE DERIVATIVE; STILBENE; THIOFLAVINE; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; AMYLOID PLAQUE; AUTORADIOGRAPHY; DEMENTIA; DIFFERENTIAL DIAGNOSIS; FRONTOTEMPORAL DEMENTIA; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; IMMUNOHISTOCHEMISTRY; NEUROFIBRILLARY TANGLE; NEUROPATHOLOGY; NONHUMAN; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); POSITRON EMISSION TOMOGRAPHY; REVIEW; SENSITIVITY AND SPECIFICITY; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY;

ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; ANIMALS; FLUORINE RADIOISOTOPES; HUMANS; PLAQUE, AMYLOID; POSITRON-EMISSION TOMOGRAPHY;

EID: 84878771121     PISSN: 15680266     EISSN: 18734294     Source Type: Journal    
DOI: 10.2174/1568026611313080004     Document Type: Review

References (107)

1. Greene, J.D.; Baddeley, A.D.; Hodges, J.R. Analysis of the episodic memory deficit in early Alzheimer's disease: evidence from the doors and people test. Neuropsychologia, 1996, 34, 537-551
2. Pillon, B.; Deweer, B.; Agid, Y.; Dubois, B. Explicit memory in Alzheimer's, Huntington's, and Parkinson's diseases. Arch. Neurol., 1993, 50, 374-379
3. Price, B.H.; Gurvit, H.; Weintraub, S.; Geula, C.; Leimkuhler, E.; Mesulam, M. Neuropsychological patterns and language deficits in 20 consecutive cases of autopsy-confirmed Alzheimer's disease. Arch. Neurol., 1993, 50, 931-937
4. Esteban-Santillan, C.; Praditsuwan, R.; Ueda, H.; Geldmacher, D.S. Clock drawing test in very mild Alzheimer's disease. J. Am. Geriatr. Soc., 1998, 46, 1266-1269
5. Kirk, A.; Kertesz, A. On drawing impairment in Alzheimer's disease. Arch. Neurol., 1991, 48, 73-77
6. Brookmeyer, R.; Gray, S.; Kawas, C. Projections of Alzheimer's disease in the United States and the public health impact of delaying disease onset. Am. J. Publ. Health, 1998, 88(9), 1337-1342
7. Hebert, L.E.; Scherr, P.A.; Bienias, J.L.; Bennett, D.A.; Evans, D.A. Alzheimer disease in the U.S. population: Prevalence estimates using the 2000 Census. Archives of Neurology, 2003, 60(8), 1119-1122.
8. Fillit, H.; Hill, J. Economics of dementia and pharmacoeconomics of dementia therapy. Am. J. Geriatr. Pharmacother., 2005, 3, 39-49
9. Klunk, W.E.; Abraham, D.J. Filamentous proteins in Alzheimer's disease: new insights through molecular biology. Psych. Dev., 1988, 6, 121-152
10. Selkoe, D.J. Alzheimer's disease: genes, proteins, and therapy. Physiol. Rev., 2001, 81, 741-766
11. Hardy, J.; Selkoe, D.J. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science, 2002, 297, 353-356
12. Vassar, R.; Bennett, B.D.; Babu-Khan, S.; Kahn, S.; Mendiaz, E.A.; Denis, P.; Teplow, D.B.; Ross, S.; Amarante, P.; Loeloff, R.; Luo Y.; Fisher, S.; Fuller, J.; Edenson, S.; Lile, J.; Jarosinski, M.A.; Biere, A.L.; Curran, E.; Burgess, T.; Louis, J.C.; Collins, F.; Treanor, J.; Rogers, G.; Citron, M. βSecretase cleavage of Alzheimer's amyloid precursor protein by the transmembrane aspartic protease BACE. Science, 1999, 286(5440), 735-741
13. De Strooper, B.; König, G. Alzheimer's disease. A firm base for drug development. Nature, 1999, 402(6761), 471-472
14. Cummings, J.L. Alzheimer's disease. N. Engl. J. Med., 2004, 351, 56-67
15. Goate, A.; Chartier-Harlin, M.C.; Mullan, M.; Brown, J.; Crawford, F.; Fidani, L.; Giuffra, L.; Haynes, A.; Irving, N.; James, L.; Mant, R.; Newton, P.; Rooke, K.; Roques, P.; Talbot, C.; Pericak-Vance, M.; Roses, A.; Williamson, R.; Rossor, M.; Owen, M.; Hardy, J. Segregation of a missense mutation in the amyloid precursor protein gene with familial Alzheimer's disease. Nature, 1991, 349, 704-706
16. Selkoe, D.J.; Podlisny, M.B. Deciphering the genetic basis of Alzheimer's disease. Annu. Rev. Genomics Hum. Genet., 2002, 3, 67-99
17. Bertram, L.; Tanzi, R.E. Of replications and refutations: The status of Alzheimer's disease genetic research. Curr. Neurol. Neurosci. Rep., 2001, 1, 442-450
18. Mann, D.M.; Jones, D.; South, P.W.; Snowden, J.S.; Neary, D. Deposition of amyloid beta protein in non-Alzheimer dementias: evidence for a neuronal origin of parenchymal deposits of beta protein in neurodegenerative disease. Acta Neuropathol., 1992, 83, 415-419
19. Naslund, J.; Haroutunian, V.; Mohs, R.; Davis, K.L; Davies, P.; Greengard, P.; Buxbaum, J.D. Correlation between elevated levels of amyloid beta-peptide in the brain and cognitive decline. J. Am. Med. Assoc., 2000, 283, 1571-1577
20. Cotman, C.W.; Pike, C.J.; Copani, A. β-amyloid neurotoxicity: A discussion of in vitro findings. Neurobiology of Aging, 1992, 13(5), 587-590
21. Yankner, B.A.; Caceres, A.; Duffy, L.K. Nerve growth factor potentials the neurotoxicity of beta amyloid. Proc. Natl. Acad. Sci. U S A, 1990, 87, 9020-9023
22. Mattson, M.P.; Cheng, B.; Davis, D.; Bryant, K.; Lieberburg, I.; Rydel, R.E. beta-Amyloid peptides destabilize calcium homeostasis and render human cortical neurons vulnerable to excitotoxicity. J. Neurosci. 1992, 12, 376-389
23. Malchiodi-Albedi, F.; Paradisi, S.; Matteucci, A.; Frank, C.; Diociaiuti, M. Amyloid Oligomer Neurotoxicity, Calcium Dysregulation, and Lipid Rafts. International Journal of Alzheimer's Disease, 2011, Article ID 906964, 17 pages
24. Chalmers, K.; Wilcock, G.K.; Love, S. APOE 4 influences the pathological phenotype of Alzheimer's disease by favouring cerebrovascular over parenchymal accumulation of A protein. Neuropathol. Appl. Neurobiol., 2003, 29, 231-8
25. Olichney, J.M.; Hansen, L.A.; Lee, J.H.; Hofstetter, C.R.; Katzman, R.; Thal, L.J. Relationship between severe amyloid angiopathy, apolipoprotein E genotype, and vascular lesions in Alzheimer's disease. Ann. N.Y. Acad. Sci., 2000, 903, 138-143
26. Kim, J.; Basak, J.M.; Holtzman, D.M. The role of apolipoprotein E in Alzheimer's disease, Neuron, 2009, 63 (3), 287-303
27. Corder, E.H.; Saunders, A.M.; Strittmatter, W.J.; Schmechel, D.E.; Gaskell, P.C.; Small, G.W.; Roses, A.D.; Haines, J.L.; Pericak-Vance, M.A. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families, Science, 1993, 261(5123), 921-923
28. Strittmatter, W.J.; Weisgraber, K.H.; Huang, D.Y.; Dong, L.M.; Salvesen, G.S.; Pericak-Vance, M.; Schmechel, D.; Saunders, A.M.; Goldgaber, D.; Roses, A.D. Binding of human apolipoprotein E to synthetic amyloid peptide: isoform-specific effects and implications for late-onset Alzheimer disease, Proc. Natl. Acad. Sci. U S A., 1993, 90 (17), 8098-8102
29. Spires, T.L.; Hyman, B.T. Transgenic models of Alzheimer's disease: learning from animals. NeuroRx., 2005, 2(3), 423-437
30. Masliah, E.; Sisk, A.; Mallory, M.; Mucke, L.; Schenk, D.; Games, D. Comparison of neurodegenerative pathology in transgenic mouse models of Alzheimer's disease: a quest for plaques and tangles. J. Neurosci., 1996, 16(18), 5795-5811
31. Richardson, J. A.; Burns, D.K. Mice overexpressing V717Fβ-amyloid precursor protein and Alzheimer's disease. Instit. for Labor. Anim. Res. J., 2002, 43 (2), 89-99
32. Sano, M.; Grossman, H.; Van Dyk, K. Preventing Alzheimer's disease: separating fact from fiction. CNS Drugs, 2008, 22, 887-902
33. Furumoto, S.; Okamura, N.; Iwata, R.; Yanai, K.; Arai, H.; Kudo, Y. Recent advances in the development of amyloid imaging agents. Curr. Top. Med. Chem., 2007, 7(18), 1773-1789
34. Cai, L.; Innis, R.B.; Pike, V.W. Radioligand development for PET imaging of β-amyloid (Aβ)-current status. Curr. Med. Chem., 2007, 14, 19-52
35. 18F Stilbenes and styrylpyridines for PET imaging of A plaques in Alzheimer's disease: a miniperspective. J. Med. Chem., 2011, 53(3), 933-941
36. Valotassiou, V.; Archimandritis, S.; Sifakis, N.; Papatriantafyllou, J.; Georgoulias, P. Alzheimer's disease: SPECT and PET tracers for beta-amyloid imaging. Curr. Alzheimer Res., 2010, 7(6), 477-486
37. Vallabhajosula, S. Positron emission tomography radiopharmaceuticals for imaging brain beta-amyloid. Semin. Nucl. Med., 2011, 41(4), 283-299
38. Mathis, C.A.; Wang, Y.; Klunk W.E. Imaging β-amyloid plaques and neurofibrillary tangles in the aging human brain. Curr. Phar. Des., 2004, 10, 1469-1492
39. 11C-labeled 6-substituted 2-arylbenzothiazoles as amyloid imaging agents. J. Med. Chem., 2003, 46, 2740-2754
40. Dishino, D.D.; Welch, M.J.; Kilbourn, M.R.; Raichle, M.E. Relationship between lipophilicity and brain extraction of C-11-labeled radiopharmaceuticals. J. Nucl. Med., 1983, 24, 1030-1038
41. Waterhouse, R.N. Determination of lipophilicity and its use as a predictor of blood-brain barrier penetration of molecular imaging agents. Mol. Imaging Biol., 2003, 5, 376-389
42. Pike, V.W. Positron-emitting radioligands for studies in vivoprobes for human psychopharmacology. J. Psychopharmacol. 1993, 7, 139-158
43. Agdeppa, E.D.; Kepe, V.; Liu, J.; Flores-Torres, S.; Satyamurthy, N.; Petric, A.; Cole, G.M.; Small, G.W.; Huang, S.-C.; Barrio J.R. Binding characteristics of radiofluorinated 6-dialkylamino-2-naphthylethylidene derivatives as positron emission tomography imaging probes for β-amyloid plaques in Alzheimer's disease. J. Neurosci. 2001, 21, RC189
44. Shoghi-Jadid K., Small, G.W.; Agdeppa, E.D.; Kepe, V.; Ercoli, L.M.; Siddarth, P.; Read, S.; Satyamurthy, N.; Petric, A.; Huang, S.C.; Barrio, J.R. Localization of neurofibrillary tangles and betaamyloid plaques in the brains of living patients with Alzheimer disease. Am. J. Geriatr. Psychiatry, 2002, 10(1), 24-35
45. Agdeppa, E.D.; Kepe, V.; Liu, J.; Small, G.W.; Huang, S.C.; Petric, A.; Satyamurthy, N.; Barrio, J.R. 2-Dialkylamino-6-acylmalononitrile substituted naphthalenes (DDNP analogs): novel diagnostic and therapeutic tools in Alzheimer's disease. Mol. Imaging Biol., 2003, 5(6), 404-417
46. Thompson, P.W.; Ye, L.; Morgenstern, J.L.; Sue, L.; Beach, T.G.; Judd, D.J.; Shipley, N.J.; Libri, V.; Lockhart, A. Interaction of the amyloid imaging tracer FDDNP with hallmark Alzheimer's disease pathologies. J. Neurochem., 2009, 109(2), 623-630
47. Barrio, J.R.; Satyamurthy, N.; Huang, S.C.; Petric, A.; Small, G.W.; Kepe, V. Dissecting molecular mechanisms in the living brain of dementia patients. Acc. Chem. Res., 2009, 42, 842-850
48. Kung, M.P.; Hou, C.; Zhuang, Z.-P.; Zhang, B.; Skovronsky, D.; Trojanowski, J.Q.; Lee, V.M.-Y.; Kung, H.F. IMPY: an improved thioflavin-T derivative for in vivo labeling of β-amyloid plaques. Brain Res., 2002, 956, 202-210
49. Zhuang, Z.P.; Kung, M-P.; Wilson, A.; Lee, C.W.; Plössl, K.; Hou, C.; Holtzman, D.M.; Kung, H.F. Structure-activity relationship of imidazo[1,2-a]pyridines as ligands for detecting β-amyloid plaques in the brain. J. Med. Chem. 2003, 46, 237-243
50. Kung, M.-P.; Hou, C.; Zhuang, Z.-P.; Cross, A.J.; Maier, D.L.; Kung, H.F. Characterization of IMPY as a potential imaging agent for beta-amyloid plaques in double transgenic PSAPP mice. Eur. J. Nucl. Med. Mol. Imaging, 2004, 31(8), 1136-1145
51. 123I-IMPY: a novel amyloid plaque-imaging agent for the diagnosis of Alzheimer's disease. J. Nucl. Med. 2006, 47, 748-754
52. 18F-labeled 6-iodo-2-(4'-N,Ndimethylamino)phenylimidazo[1,2-a]pyridine derivatives as prospective radioligands for beta-amyloid in Alzheimer's disease. J. Med. Chem., 2004, 47, 2208-2218
53. 18F-labeled imidazo[1,2-a]pyridine analogues as potential agents for imaging β-amyloid in Alzheimer's disease. Bioorg. Med. Chem. Lett., 2006, 16, 3015-3018
54. Klunk, W.E.; Wang, Y.; Huang, G.F.; Debnath, M.L.; Holt, D.P.; Mathis, C.A. Uncharged thioflavin-T derivatives bind to amyloidbeta protein with high affinity and readily enter the brain. Life Sci., 2001, 69(13), 1471-1484
55. Mathis, C.A.; Bacskai, B.J.; Kajdasz, S.T.; McLellan, M.E.; Frosch, M.P.; Hyman, B.T.; Holt, D.P.; Wang, Y.; Huang, G.F.; Debnath, M.L.; Klunk, W.E. A lipophilic thioflavin-T derivative for positron emission tomography (PET) imaging of amyloid in brain. Bioorg. Med. Chem. Lett., 2002, 12(3), 295-298
56. Klunk, W.E.; Engler, H.; Nordberg, A.; Wang, Y.; Blomqvist, G.; Holt, D.P.; Bergstrom, M.; Savitcheva, I.; Huang, G.F.; Estrada, S.; Ausen, B.; Debnath, M.L.; Barletta, J.; Price, J.C.; Sandell, J.; Lopresti, B.J.; Wall, A.; Koivisto, P.; Antoni, G.; Mathis, C.A.; Langstrom, B. Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B. Ann. Neurol., 2004, 55, 306-319
57. Price, J.C.; Klunk, W.E.; Lopresti, B.J.; Lu, X.; Hoge, J.A.; Ziolko, S.K.; Holt, D.P.; Meltzer, C.C.; DeKosky, S.T.; Mathis, C.A. Kinetic modeling of amyloid binding in humans using PET imaging and Pittsburgh Compound-B. J. Cereb. Blood Flow Metab., 2005, 25(11), 1528-1547
58. 11C-PIB positron emission tomography study. Ann. Neurol., 2006, 60(1), 145-147
59. Rowe, C.C.; Ng, S.; Ackermann, U.; Gong, S.J.; Pike, K.; Savage, G.; Cowie, T.F.; Dickinson, K.L.; Maruff, P.; Darby, D.; Smith, C.; Woodward, M.; Merory, J.; Tochon-Danguy, H.; O'Keefe, G.; Klunk, W.E.; Mathis, C.A.; Price, J.C.; Masters, C.L.; Villemagne, V.L. Imaging beta-amyloid burden in aging and dementia. Neurology, 2007, 68, 1718-1725
60. Ikonomovic, M.D.; Klunk, W.E.; Abrahamson, E.E.; Mathis, C.A.; Price, J.C.; Tsopelas, N.D.; Lopresti, B.J.; Ziolko, S.; Bi, W.; Paljug, W.R.; Debnath, M.L.; Hope, C.E.; Isanski, B.A.; Hamilton, R.L.; Dekosky, S.T. Post-mortem correlates of in vivo PIB-PET amyloid imaging in a typical case of Alzheimer's disease. Brain, 2008, 131, 1630-45
61. Klunk, W.E.; Mathis, C.A. The future of amyloidimaging: a tale of radionuclides and tracer proliferation. Curr. Opin. Neurol., 2008, 21, 683-687
62. 11C]PIB-amyloid binding and levels of Aβ40 and Aβ42 in postmortem brain tissue from Alzheimer patients. Neurochem. Int., 2008, 54, 347-357
63. 18F-FDDNP PET. J. Nucl. Med., 2009, 50(2), 191-197
64. Engler, H.; Santillo, A. F.; Wang, S.X.; Lindau, M.; Savitcheva, I.; Nordberg, A.; Lannfelt, L.; Långström, B.; Kilander, L. In vivo amyloid imaging with PET in frontotemporal dementia. Eur. J. Nucl. Med. Mol. Imaging., 2008, 35(1), 100-106
65. Mathis, C.A.; Ikonomovicb, M.D.; Debnath, M.L. et al. Comparison of the binding of 3'-F-PIB and PIB in human brain homogenates. Neuroimage, 2008, 41 (Suppl 2), T113-T114
66. 18F-GE067: a radioligand for in vivo brain amyloid imaging. J. Nucl. Med., 2009, 50, 818-822
67. Mathis, C.; Lopresti, B.; Mason, N.; Price, J.; Flatt, N.; Bi, W.; Ziolko, S.; DeKosky, S.; Klunk, W. Comparison of the amyloid imaging agents [F-18]3'-F-PIB and [C-11]PIB in Alzheimer's disease and control subjects. J. Nucl. Med., 2007, 48(Suppl 2), 56P
68. 18F-flutemetamol in healthy volunteers and patients with probable Alzheimer disease. J. Nucl. Med., 2009, 50(8), 1251-1259
69. 18F-flutemetamol amyloid imaging in Alzheimer disease and mild cognitive impairment: a phase 2 trial. Ann. Neurol., 2010, 68(3), 319-329
70. 18F-labeled 2-phenylbenzothiazoles as positron emission tomography imaging agents for amyloid plaques in Alzheimer's disease. J. Med. Chem., 2009, 52(5):1428-1437
71. Chitneni, S.K.; Serdons, K.; Evens, N.; Fonge, H.; Celen, S.; Deroose, C.M.; Debyser, Z.; Mortelmans, L.; Verbruggen, A.M.; Bormans, G.M. Efficient purification and metabolite analysis of radiotracers using high-performance liquid chromatography and online solid-phase extraction. J. Chromatogr. A., 2008, 1189(1-2), 323-331
72. 18F-labeled aminophenylbenzothiazoles as amyloid imaging agents. J. Med. Chem., 2009, 52, 7090-7102
73. Johnson, A.E.; Jeppsson, F.; Sandell, J.; Wensbo, D.; Neelissen, J.A.; Juréus, A.; Ström, P.; Norman, H.; Farde, L.; Svensson, S.P. AZD2184: a radioligand for sensitive detection of beta-amyloid deposits. J. Neurochem., 2009, 108(5), 1177-1186
74. 11C-PET imaging agents for beta-amyloid plaques. Bioorg Med Chem Lett., 2010, 20(6), 1976-1980
75. 18F-PET imaging agents for β-amyloid plaques. Bioorg. Med. Chem. Lett., 2012, 22, 4332-4337
76. Kung, H.F.; Lee, C.-W.; Zhuang, Z.P.; Kung, M.P.; Hou, C.; Plossl, K. Novel stilbebes as probes for amyloid plaques. J. Am. Chem. Soc., 2001, 123, 12740-12741
77. 11C]SB-13 PET. Am. J. Geriatr. Psychiatry, 2004, 12, 584-595
78. Kung M.P.; Hou, C.; Zhuang, Z.P.; Skovronsky, D.; Kung, H.F. Binding of two potential imaging agents targeting amyloid plaques in postmortem brain tissues of patients with Alzheimer's disease. Brain Res., 2004, 1025, 98-105
79. Zhang, W.; Oya, S.; Kung, M.-P.; Hou, C.; Maier, D.L.; Kung, H.F. F-18 Stilbenes as PET imaging agents for detecting β-amyloid plaques in the brain. J. Med. Chem., 2005, 48, 5980-5988
80. Zhang, W.; Oya, S.; Kung, M.-P.; Hou, C.; Maier, D.L.; Kung, H.F. F-18 Polyethyleneglycol stilbene as PET imaging agents targeting A aggregates in the brain. Nucl. Med. Biol., 2005, 32, 799-809
81. Stephenson, K.A.; Chandra, R.; Zhuang, Z.P.; Hou, C.; Oya, S.; Kung, M.P.; Kung, H.F. Fluro-pegylated (FPEG) imaging agents targeting Abeta aggregates. Bioconjugate Chem., 2007, 18, 238-246
82. 18F-BAY94-9172, a novel PET tracer: proof of mechanism. Lancet Neurol., 2008, 7, 129-135
83. 18F-BAY94-9172. J. Nucl. Med., 2009, 50(2), 309-315
84. Barthel, H.; Gertz, H. J.; Dresel, S.; Peters, O.; Bartenstein, P.; Buerger, K.; Hiemeyer, F.; Wittemer-Rump, S.M.; Seibyl, J.; Reininger, C.; Sabri, O. Cerebral amyloidPET with florbetaben (18F) in patients with Alzheimer's disease and healthy controls: a multicentre phase 2 diagnostic study. Lancet Neurol., 2011, 10(5), 424-435
85. [18]F-florbetaben in Alzheimer disease and other dementias. J. Nucl. Med., 2011, 52(8), 1210-1217
86. 18F-Labeled styrylpyridines as PET agents for amyloid plaque imaging. Nucl. Med. Biol., 2007, 34, 89-97
87. Chandra, R.; Oya, S.; Kung, M.P.; Hou, C.; Jin, L.W.; Kung, H.F. New diphenylacetylenes as probes for positron emission tomographic imaging of amyloid plaques. J. Med. Chem., 2007, 50, 2415-2423
88. Qu, W.; Choi, S.; Hou, C.; Zhuang, Z.; Oya, S.; Zhang, W.; Kung, M.P.; Manchandra, R.; Skovronsky, D. M.; Kung, H.F. Synthesis and evaluation of indolinyl-and indolylphenylacetylenes as PET imaging agents for β-amyloid plaques. Bioorg. Med. Chem. Lett., 2008, 18, 4823-4827
89. 18F-labeled amyloidimaging agents in Alzheimer's disease patients and healthy elderly controls. J. Nucl. Med., 2008, 49, 34pp
90. 18F-AV-45: a PET agent for A plaques in the brain. J. Nucl. Med., 2009, 50, 1887-1894
91. 18F-AV-45 (florbetapir F 18). J. Nucl. Med., 2010, 51, 913-920
92. 18F), a PET imaging agent that binds to amyloid plaques for the potential detection of Alzheimer's disease. IDrugs, 2010, 13, 890-899
93. Fleisher, A.S.; Chen, K.; Liu, X.; Roontiva, A.; Thiyyagura, P.; Ayutyanont, N.; Joshi, A.D.; Clark, C.M.; Mintun, M.A.; Pontecorvo, M.J.; Doraiswamy, P.M.; Johnson, K.A.; Skovronsky, D.M.; Reiman, E.M. Using positron emission tomography and florbetapir F18 to image cortical amyloid in patients with mild cognitive impairment or dementia due to Alzheimer disease. Arch. Meurol., 2011, 68, 1404-1411
94. Lister-James, J.; Pontecorvo, M. J.; Clark, C.; Joshi, A.D.; Mintun, M.A.; Zhang, W.; Lim, N.; Zhuang, Z.; Golding, G.; Choi, S.R.; Benedum, T.E.; Kennedy, P.; Hefti, F.; Carpenter, A.P.; Kung, H.F.; Skovronsky, D.M. Florbetapir f-18: a histopathologically validated Beta-amyloid positron emission tomography imaging agent. Semin. Nucl. Med., 2011, 41, 300-304
95. Clark, C.M.; Schneider, J.A.; Bedell, B.J.; Beach, T.G.; Bilker, W.B.; Mintun, M.A.; Pontecorvo, M.J.; Hefti, F.; Carpenter, A.P.; Flitter, M.L.; Krautkramer, M.J.; Kung, H.F.; Coleman, R.E.; Doraiswamy, P.M.; Fleisher, A.S.; Sabbagh, M.N.; Sadowsky, C.H.; Reiman, E.P.; Zehntner, S.P.; Skovronsky, D.M. Use of florbetapir-PET for imaging beta-amyloid pathology. J. Am. Med. Assoc. 2011, 305, 275-283
96. Joshi, A.D.; Pontecorvo, M.J.; Clark, C.M.; Carpenter, A.P.; Jennings, D.L.; Sadowsky, C.H.; Adler, L.P.; Kovnat, K.D.; Seibyl, J.P.; Arora, A.; Saha, K.; Burns, J.D.; Lowrey, M.J.; Mintun, M.A.; Skovronsky, D.M. Performance characteristics of amyloid PET with florbetapir F 18 in patients with alzheimer's disease and cognitively normal subjects. J. Nucl. Med., 2012, 53, 378-384
97. 18F-Polypegylated Styrylpyridines As Imaging Agents for A Plaques in Cerebral Amyloid Angiopathy (CAA). J. Med. Chem., 2011, 54, 8085-8098
98. Ono, M.; Kung, M.P.; Hou, C.; Kung, H.F. Benzofuran derivatives as Aβ-aggragate-specific imaging agents for Alzheimer's disease. Nucl. Med. Biol., 2002, 29, 633-642
99. Ono, M.; Kawashima, H.; Nonaka, A.; Kawai, T.; Haratake, M.; Mori, H.; Kung, M.P.; Kung, H.F.; Saji, H.; Nakayama, M.; Novel benzofuran derivatives for PET imaging of β-amyloid plaques in Alzheimer's disease brains. J. Med. Chem., 2006, 49, 2725-2730
100. Cheng, Y.; Ono, M.; Kimura, H.; Kagawa, S.; Nishii, R.; Kawashima, H.; Saji, H. Fluorinated benzofuran derivatives for PET imaging of β-amyloid plaques in Alzheimer's disease brains. ACS Med. Chem. Lett., 2010, 1, 321-325
101. 18F-labeled pyridyl benzofuran derivative for imaging ofβ-amyloid plaques in Alzheimer's brains. Bioorg. Med. Chem. Lett., 2010, 20, 6141-6144
102. 18F-labeled benzofuran derivatives with improved properties for positron emission tomography (PET) imaging ofβ-amyloid plaques in Alzheimer's brains. J. Med. Chem., 2011, 54, 2971-2979
103. Juréus, A.; Swahn, B.M.; Sandell, J.; Jeppsson, F.; Johnson, A.E.; Johnström, P.; Neelissen, J.A.M.; Sunnemark, D.; Farde, L.; Svensson, S.P.S. Characterization of AZD4694, a novel fluorinated A plaque neuroimaging PET radioligand. J. Neurochem., 2010, 114, 784-794
104. 18F-AZD4694, an amyloid-specific PET radioligand. J. Nucl. Med., 2012, 53, 415-424
105. Shimadzu, H.; Suemoto, T.; Suzuki, M.; Shiomitsu, T.; Okamura, N.; Kudo, Y.; Sawada, T. Novel probes for imaging amyloid-: F-18 and C-11 labeling of 2-(4-aminostyryl)benzoxazole derivatives. J. Label. Compd. Radiopharm., 2004, 47, 181-190
106. 18F]Fluoroazabenzoxazoles as potential amyloid plaque PET tracers: synthesis and in vivo evaluation in rhesus monkey. Nucl. Med. Biol., 2011, 38, 1193-1203
107. 18F-labeled benzoxazole derivatives as potential positron emission tomography probes for imaging of cerebral β-amyloid plaques in Alzheimer's disease. J. Med. Chem., 2012, 55, 9136-9145.